GSK press releases
Follow
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Multiple real-world studies show consistent high effectiveness of Vocabria + Rekambys across a broad range of populations.
